[Present possibilities of treatment of chronic B-cell lymphocytic leukemia]

Chronic lymphocytic leukemia (CLL) belongs to the group of diseases with a malignant course and bad outcome. Clinically, the course of CLL exceptionally varies, survival ranges from one to twenty years. The choice of treatment for those affected with CLL is not simple because of the different course of the disease in individual patients and because of the different attitudes in the application of available means of therapy. By introducing antitumor drugs (Interferon alpha-2, Interleukin 2b), new chemotherapeutics (Fludarabin, Pentostatin), monoclonal antibodies and especially by introducing allogenic bone marrow transplantation into therapy, new possibilities are attained for the more efficient treatment of these patients.